# STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE

> **NCT02328391** · — · UNKNOWN · sponsor: **Grupo Gallego de Cancer de Pulmon** · enrollment: 51 (estimated)

## Conditions studied

- Carcinoma, Squamous Cell

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02328391
- **Lead sponsor:** Grupo Gallego de Cancer de Pulmon
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-09
- **Primary completion:** 2015-03
- **Final completion:** 2015-12
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2014-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02328391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02328391, "STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02328391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*